STADA’s Partnership With Calliditas Therapeutics

McDermott Will & Emery advised STADA Arzneimittel on the deal.

STADA Arzneimittel AG closed a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN). The cooperation extends to the European Economic Area, Switzerland and the United Kingdom. It has a total value of EUR 97.5 million ($ 115 million) plus royalties.

STADA relies on a three-pillar strategy consisting of generics, specialty pharmaceuticals and non-prescription consumer healthcare products.

STADA sells products in about 120 countries worldwide. Calliditas is a Nasdaq-listed clinical-stage pharmaceutical company based in Sweden and focusing on the development of orphan drugs.

The McDermott team advising STADA was led by Deniz Tschammler (Commercial/Regulatory, Munich; Picture) and Monika Richter (Life Sciences/Licensing, Frankfurt) and worked very closely with STADA’s inhouse team which comprised Christoph C. Dengler (EVP Global Legal / General Counsel), Marcus Heppner (Director Legal Affairs – Global BD&L and M&A) and Friederike Bockmann (Senior Legal Counsel).

Involved fees earner: Monika Emilia Richter – McDermott Will & Emery; Deniz Tschammler – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: STADA Arzneimittel AG;

Author: Federica Tiefenthaler